However, the antitumor effects of osteonectin-promoter–mediated gene therapy for prostate cancer bone metastasis without other organ toxicity might be achieved by understanding the cis- and trans-acting factors in the hON promoter. The gene discussed is SPARC; the disease is prostate cancer.